Dr. James Brugarolas is guest lecturer for Yale School of Medicine Grand Rounds


Kidney Cancer Program Director James Brugarolas is the guest lecturer for the Yale School of Medicine Pathology Grand Rounds. The title of his presentation - At the Crossroads of Epigenetics and Angiogenesis: Targting the Undruggable.

DoD awards more than $2.7 million to six UTSW investigators for kidney cancer research


The Department of Defense Congressionally Directed Kidney Cancer Research Program awards more than $2.7 million in research funding to six UTSW Kidney Cancer Program investigators.

Drs. Payal Kapur and Satwick Rajaram received an Idea Development Award ($980,839) to evaluate digital pathology and deep learning to predict treatment response. Dr. Srinivas Malladi received an Early Career Idea Development Award ($983,478) to delineate latency and relapse determinants in metastatic clear cell renal cell carcinoma (ccRCC). Dr. Qing Zhang received a Concept Award ($163,670) to identify functionally important enhancers in kidney cancer. Finally, Drs. Jong-Sun Lee and Faeze Saatchi from the Mendell and Brugarolas Labs, respectively, received Postdoctoral Awards ($319,800/Lee; $319,307/Saatchi) to understand the role of nonlongcoding RNAs in kidney cancer and identify molecular mechanisms underlying HIF2-independent tumorigenesis. 

* The views expressed in this press release/article are those of the author's and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.

2019 Nobel Prize winner Dr. William Kaelin speaks at University Lecture Series


2019 Nobel Prize winner and Harvard Medical School Professor William Kaelin, M.D., is the guest speaker for UT Southwestern's University Lecture Series. Kidney Cancer Program Director (and Kaelin Lab alumnus) James Brugarolas is the event moderator. Dr. Kaelin is recognized for his landmark work involving the VHL tumor suppressor gene.   

KCP hosts 7th annual Advisory Board meeting


Members of the Kidney Cancer Program's External Scientific Advisory Board convened to discuss the program's latest research initiatives and proposed SPORE projects.

New immunotherapy drug boosts innate immune system to fight cancer


A newly released study by Jinming Gao, professor of Oncology, Pharmacology, and Otolarynology, shows how a novel, nanoparticle-based drug may be more effective at engaging the body's innate immune system to fight cancer. The drug's unique and prolonged binding to the STING protein was associated with longer innate immune activation, demonstrating a more effective T cell response against solid tumors. 

Collaborative study highlights imortance of complement system in renal cancer


A collaborative study with Texas Tech University Health Sciences Center that builds upon a prior KCP discovery of an inflammed subtype of renal cancer (Wang et al., Cancer Discov 2018) shows increased deposition of complement proteins in inflamed renal tumors. The data suggest that complement proteins, which are associated with poor prognosis, may suppress an adaptive immune response and could be targeted in combination with immune checkpoint inhibitors.

CDMRP-funded National Kidney Cancer Academy hosts meeting for new investigators


November 5 marks the first workshop for kidney cancer investigators participating in the National Kidney Cancer Academy, funded by the CDMRP's (Congressionally Directed Medical Research Program) Kidney Cancer Research Program. New investigator award recipients Drs. David Braun (Dana-Farber Cancer Institute), Abishek Chakraborty (Cleveland Clinic), and Lucas Salas (Dartmouth Geisel School of Medicine) discussed their research plans with Dr. Brian Rini (Vanderbilt-Ingram Cancer Center), Dean of the Academy, along with members of the Advisory Board, which is chaired by KCP Director Dr. James Brugarolas, and other kidney cancer experts.

Novel ccRCC evolutionary model


Drawing from a recent report of ccRCC subtypes based on gene expression (from a Genentech-sponsored clinical trial), as well as pioneering genomic discoveries and mouse models from the Kidney Cancer Program, Drs. Brugarolas and Kapur present an updated evolutionary model of clear cell renal cell carcinoma development. Article 

Discovery shows connection between autoimmune side effect and improved immunotherapy response for kidney cancer patients


In a newly published study, KCP investigators show a link between immune attacks against the kidneys and positive response rates to immunothrapy - a discovery which may hold implications for other cancers.

Dr. James Chen receives Cancer Research Institute Award for groundbreaking discoveries on innate immunity


Biochemist Dr. Zhijian "James" Chen receives the 2020 William B. Coley Award in recognition for his work on the cGAS-STING pathway and its potential to improve cancer immunotherapies.